Cue Biopharma officer files initial Form 3

Cue Biopharma, Inc. filed an initial Form 3 for officer Michael Vincent Meluzio, who serves as VP and Principal Accounting Officer.

Rhea-AI Filing Summary

Cue Biopharma, Inc. filed an initial Form 3 for officer Michael Vincent Meluzio, who serves as VP and Principal Accounting Officer. The filing reports that he is an officer but does not list any equity transactions or current holdings in either common stock or derivatives.

Key Terms

Form 3, beneficial ownership, Principal Accounting Officer

3 terms

Form 3 regulatory

"Cue Biopharma, Inc. filed an initial Form 3 for officer Michael Vincent Meluzio"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"It is an initial beneficial ownership report and does not list any specific share holdings"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Principal Accounting Officer financial

"serves as VP and Principal Accounting Officer"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for Cue Biopharma (CUE) disclose about Michael Vincent Meluzio?

The Form 3 shows that Michael Vincent Meluzio is an officer of Cue Biopharma, serving as VP and Principal Accounting Officer. It is an initial beneficial ownership report and does not list any specific share holdings or recent transactions in the company’s securities.

Does the Cue Biopharma (CUE) Form 3 show any stock purchases or sales by Michael Vincent Meluzio?

No, the Form 3 does not show any stock purchases or sales by Michael Vincent Meluzio. The transaction summary indicates zero buy, sell, exercise, gift, tax-withholding, or restructuring transactions, reflecting only his status as a reporting officer of Cue Biopharma.

Are any derivative securities reported for Michael Vincent Meluzio in Cue Biopharma’s Form 3?

No derivative securities are reported for Michael Vincent Meluzio in this Form 3. The derivativeSummary section is empty and the transactionSummary shows zero derivative transactions, indicating no options, warrants, or similar instruments are disclosed in this initial ownership statement.

What is Michael Vincent Meluzio’s role at Cue Biopharma (CUE) according to the Form 3?

According to the Form 3, Michael Vincent Meluzio is an officer of Cue Biopharma with the title VP, Principal Accounting Officer. This role means he is responsible for principal accounting functions and must report his beneficial ownership in the company’s securities to the SEC.

Does the Cue Biopharma (CUE) Form 3 indicate any significant insider activity?

The Form 3 does not indicate significant insider activity. All transaction counts and share amounts for buys, sells, exercises, gifts, tax withholding, and restructurings are zero, and netBuySellDirection is noted as neutral, reflecting the absence of reportable trades in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 05:48 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Meluzio Michael Vincent

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2026

3. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Prin. Accounting Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Michael Meluzio	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)